Literature DB >> 20027086

An "all 5-mm ports" versus conventional ports approach to laparoscopic cholecystectomy and Nissen fundoplication: a randomized clinical trial.

Muhammad Hasan Abbas1, Ayman Hamade, Rana Nadeem, Basil Ammori.   

Abstract

BACKGROUND: Although needlescopic surgery may reduce postoperative pain, the use of 3-mm instruments is cumbersome and has not gained popularity. We have described an "all 5-mm ports" approach to laparoscopic cholecystectomy (LC) and Nissen fundoplication (LNF).
METHODS: Selected patients were randomized to undergo LC or LNF using either the "all 5-mm ports" approach (group 1) or the conventional approach (group 2) that used two 10-mm ports and two or three 5-mm ports. The patients and investigator were blinded to the size of ports used.
RESULTS: Forty patients (20 in each group) were randomized. The groups were comparable for age, sex, and type and duration of surgery. No significant reductions in analgesic requirements at 7 days or in pain scores at 4 and 24 hours postoperatively were detected with the "all 5-mm ports" approach. However, the cosmetic satisfaction scores with the body (P=0.029), incisions (P=0.015), and scars (P=0.023) 4 weeks after surgery were significantly higher in group 1.
CONCLUSIONS: The "all 5-mm ports" approach to LC and LNF in selected patients did not offer clear advantages over the conventional approach in terms of postoperative pain or analgesic requirements. Nevertheless, the former approach enjoyed a superior cosmetic outcome and patient acceptability.

Entities:  

Mesh:

Year:  2009        PMID: 20027086     DOI: 10.1097/SLE.0b013e3181bd9435

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  1 in total

1.  Cosmetic Outcome of Robotic Surgery Compared to Laparoscopic Surgery for Benign Gynecologic Disease.

Authors:  Esra Ozbasli; Ozguc Takmaz; Nazlı Albayrak; Mete Gungor Md
Journal:  JSLS       Date:  2022 Apr-Jun       Impact factor: 2.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.